8/105 sources · 3 publishersUpdated Nov 3, 05:55 UTC
Grifols posts Q3 2026 revenue growth, margin expansion and sub‑4x leverage
Grifols reported third‑quarter 2026 revenue of €2.04 billion, up 8.4% at constant currency, and adjusted EBITDA of €538 million, giving a margin of 26.4%. Biopharma sales rose 10.3% while albumin fell 13.2% amid China market pressure. Leverage improved to 3.98 × and the board approved an interim dividend of €0.15 per share.
Why it matters
The company said it remains on track to meet its 2026 full‑year adjusted EBITDA margin guidance of 25%, which signals continued profitability for investors. The lower leverage and dividend payout improve the share’s cash‑flow profile and may support the stock’s valuation.
Key facts
- 1Quarterly revenue was €2,040 million, up 8.4% at constant currency. investing.com
- 2Adjusted EBITDA for the quarter was €538 million, yielding a margin of 26.4%. investing.com
- 3Leverage ratio fell to 3.98 ×, the first time below 4.0 × in recent years. investing.com
- 4The board approved an interim dividend of €0.15 per share. investing.com
- 5Biopharma revenue grew 10.3% at constant currency in the quarter. investing.com
- 6Albumin revenue declined 13.2% in the quarter. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.